John A Lawson

List of Publications by Year
in descending order

60 papers	2,954 citations	257357 24 h-index	175177 52 g-index
62 all docs	62 docs citations	62 times ranked	3287 citing authors

#	Article	IF	Citations
1	Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. Haematologica, 2022, 107, 635-643.	1.7	16
2	Expert advice for prescribing cannabis medicines for patients with epilepsyâ€"drawn from the Australian clinical experience. British Journal of Clinical Pharmacology, 2022, 88, 3101-3113.	1.1	8
3	Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia, 2022, 63, 1736-1747.	2.6	11
4	Accelerated long-term forgetting in children with temporal lobe epilepsy: A timescale investigation of material specificity and executive skills. Epilepsy and Behavior, 2022, 129, 108623.	0.9	4
5	Congenital subpendymal giant cell astrocytoma in children with tuberous sclerosis complex: growth patterns and neurological outcome. Pediatric Research, 2021, 89, 1447-1451.	1.1	5
6	Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. Neurology, 2021, 96, e1770-e1782.	1.5	53
7	TuberOus SClerosis registry to increase disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2021, 12, 630378.	1.1	10
8	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. JAMA Neurology, 2021, 78, 285.	4.5	139
9	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease awareness (TOSCA). Orphanet Journal of Rare Diseases, 2021, 16, 301.	1.2	15
10	The need for improved management of status epilepticus in children in Australia: Time from seizure onset to treatment is consistently delayed. Journal of Paediatrics and Child Health, 2021, , .	0.4	3
11	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. Frontiers in Neurology, 2021, 12, 697467.	1.1	13
12	Clustered mutations in the GRIK2 kainate receptor subunit gene underlie diverse neurodevelopmental disorders. American Journal of Human Genetics, 2021, 108, 1692-1709.	2.6	18
13	Adjunctive everolimus therapy for tuberous sclerosis complexâ€associated refractory seizures: Results from the postextension phase of EXISTâ€3. Epilepsia, 2021, 62, 3029-3041.	2.6	16
14	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Frontiers in Neurology, 2020, 11, 972.	1.1	27
15	Successful epilepsy surgery for tuberous sclerosis complex evaluated by stereoelectroencephalography. Epileptic Disorders, 2020, 22, 633-641.	0.7	1
16	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. Journal of Neurodevelopmental Disorders, 2020, 12, 24.	1.5	16
17	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. Frontiers in Neurology, 2020, 11, 904.	1.1	20
18	Accelerated long-term forgetting in children with genetic generalized epilepsy: The temporal trajectory and contribution of executive skills. Epilepsy and Behavior, 2020, 113, 107471.	0.9	8

#	Article	IF	Citations
19	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. Frontiers in Neurology, 2020, 11, 603.	1.1	7
20	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. Frontiers in Neurology, 2019, 10, 821.	1.1	18
21	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. Frontiers in Neurology, 2019, 10, 705.	1.1	22
22	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. Frontiers in Neurology, 2019, 10, 1144.	1.1	11
23	The TOSCA Registry for Tuberous Sclerosisâ€"Lessons Learnt for Future Registry Development in Rare and Complex Diseases. Frontiers in Neurology, 2019, 10, 1182.	1.1	3
24	Facial emotion perception and social competence in children (8 to 16â€¯years old) with genetic generalized epilepsy and temporal lobe epilepsy. Epilepsy and Behavior, 2019, 100, 106301.	0.9	10
25	Management of status epilepticus in children prior to medical retrieval: Deviations from the guidelines. Journal of Paediatrics and Child Health, 2019, 55, 1458-1462.	0.4	5
26	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrology Dialysis Transplantation, 2019, 34, 502-508.	0.4	55
27	Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. Molecular Genetics & Genomic Medicine, 2018, 6, 186-199.	0.6	83
28	Everolimus dosing recommendations for <scp>tuberous sclerosis complexâ€“</scp>associated refractory seizures. Epilepsia, 2018, 59, 1188-1197.	2.6	41
29	The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review. Reviews in the Neurosciences, 2018, 29, 295-301.	1.4	17
30	Everolimus for treatment-refractory seizures in TSC. Neurology: Clinical Practice, 2018, 8, 412-420.	0.8	85
31	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet Journal of Rare Diseases, 2018, 13, 157.	1.2	106
32	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex â€“ Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. Frontiers in Pharmacology, 2018, 9, 964.	1.6	22
33	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child and Adolescent Health, 2018, 2, 495-504.	2.7	77
34	Cannabis for paediatric epilepsy: challenges and conundrums. Medical Journal of Australia, 2018, 208, 132-136.	0.8	6
35	Theory of Mind and social competence in children and adolescents with genetic generalised epilepsy (GGE): Relationships to epilepsy severity and anti-epileptic drugs. Seizure: the Journal of the British Epilepsy Association, 2018, 60, 96-104.	0.9	23
36	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 2018, 22, 1066-1073.	0.7	54

#	Article	IF	Citations
37	Outcomes of deviation from treatment guidelines in status epilepticus: A systematic review. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 147-153.	0.9	32
38	Cannabidiol for treating drugâ€resistant epilepsy in children: the New South Wales experience. Medical Journal of Australia, 2018, 209, 217-221.	0.8	28
39	Therapeutic use of medicinal cannabis in difficult to manage epilepsy. British Journal of Clinical Pharmacology, 2018, 84, 2488-2490.	1.1	8
40	TuberOus SClerosis registry to increase disease Awareness (TOSCA) â€“ baseline data on 2093 patients. Orphanet Journal of Rare Diseases, 2017, 12, 2.	1.2	166
41	Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome. Pediatric Neurology, 2017, 76, 20-26.	1.0	27
42	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	1.0	80
43	GRIN2Bencephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. Journal of Medical Genetics, 2017, 54, 460-470.	1.5	190
44	Frequency and predictors of psychological distress after a diagnosis of epilepsy: A community-based study. Epilepsy and Behavior, 2017, 75, 190-195.	0.9	20
45	Eye movement disorders are an early manifestation of <scp>CACNA</scp>1A mutations in children. Developmental Medicine and Child Neurology, 2016, 58, 639-644.	1.1	58
46	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet, The, 2016, 388, 2153-2163.	6.3	554
47	Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth. Pediatric Dermatology, 2016, 33, 536-542.	0.5	18
48	The Severity of Gliosis in Hippocampal Sclerosis Correlates with Pre-Operative Seizure Burden and Outcome After Temporal Lobectomy. Molecular Neurobiology, 2016, 53, 5446-5456.	1.9	17
49	Exploring carer perceptions of training in out-of-hospital use of buccal midazolam for emergency management of seizures (2008-2012). Journal of Paediatrics and Child Health, 2015, 51, 704-707.	0.4	8
50	Ten-Year Single-Center Experience of the Ketogenic Diet: Factors Influencing Efficacy, Tolerability, and Compliance. Journal of Pediatrics, 2015, 166, 1030-1036.e1.	0.9	66
51	Anti-N-methyl-D-aspartate encephalitis â€“ a case study of symptomatic progression. Australasian Psychiatry, 2015, 23, 422-425.	0.4	5
52	Response to â€œAbout Focal Cortical Dysplasia (FCD) type IIIaâ€. Epilepsy Research, 2014, 108, 1958-1959.	0.8	0
53	Mammalian Target of Rapamycin Inhibitors for Intractable Epilepsy and Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. Journal of Pediatrics, 2014, 164, 1195-1200.	0.9	139
54	Clinicopathological associations in temporal lobe epilepsy patients utilising the current ILAE focal cortical dysplasia classification. Epilepsy Research, 2014, 108, 1345-1351.	0.8	25

#	Article	IF	Citations
55	Managing tuberous sclerosis in the Asia-Pacific region: Refining practice and the role of targeted therapy. Journal of Clinical Neuroscience, 2014, 21, 1180-1187.	0.8	6
56	The Health-Related Quality of Life of Children with Refractory Epilepsy: A Comparison of Those With and Without Intellectual Disability. Epilepsia, 2001, 42, 621-628.	2.6	145
57	Cerebral and Cerebellar Volume Reduction in Children with Intractable Epilepsy. Epilepsia, 2000, 41, 1456-1462.	2.6	96
58	Validation of a New Quality of Life Measure for Children with Epilepsy. Epilepsia, 2000, 41, 765-774.	2.6	185
59	ILAE-Defined Epilepsy Syndromes in Children: Correlation with Quantitative MRI. Epilepsia, 1998, 39, 1345-1349.	2.6	33
60	Quantitative MRI in Outpatient Childhood Epilepsy. Epilepsia, 1997, 38, 1289-1293.	2.6	20